Cerebras
CBRS
$209.85
-2.71%
Cerebras Systems Inc. is an AI company that designs and builds the world's largest semiconductor chips and AI supercomputers for training and inference, targeting the high-performance AI infrastructure market. As a niche player challenging Nvidia's dominance, Cerebras differentiates itself with its wafer-scale engine technology and strategic partnerships with OpenAI and AWS. The stock, which IPO'd in May 2026, has been highly volatile, with investors debating its massive revenue growth potential against its steep valuation and path to profitability. Recent headlines highlight a $25 billion backlog and strong revenue surge, but also caution over gross margin guidance and the sustainability of its AI-driven growth narrative.…
CBRS
Cerebras
$209.85
Related headlines
Investment Opinion: Should I buy CBRS Today?
Rating: Hold. The stock is a high-risk, high-reward speculative growth play. Analyst consensus is Strong Buy with an average target of $290.73, implying 32.8% upside, but the extreme valuation and financial instability warrant caution. The thesis is that Cerebras can sustain triple-digit revenue growth and achieve profitability, but the risk of de-rating is significant.
Sign up to view all
CBRS 12-Month Price Forecast
Cerebras has exceptional growth but at an extreme valuation. The AI infrastructure market is expanding, but competition and profitability concerns are real. The stance is neutral because the risk-reward is balanced; upside exists if growth continues, but downside is significant if sentiment shifts. Upgrade to bullish if revenue growth exceeds 100% and margins improve; downgrade to bearish if growth falls below 50% or cash burn accelerates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cerebras's 12-month outlook, with a consensus price target around $291.64 and implied upside of +39.0% versus the current price.
Average Target
$291.64
0 analysts
Implied Upside
+39.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$209 - $330
Analyst target range
Cerebras has coverage from 11 analysts, with a consensus recommendation of 'Strong Buy' and a mean recommendation score of 1.45 (where 1 is strong buy and 5 is sell). The average target price is $290.73, implying an upside of 32.8% from the current price of $218.98. The target range spans from a low of $209.00 to a high of $325.00, indicating a wide dispersion of views. The high target suggests optimism about the company's growth trajectory and potential market share gains, while the low target reflects concerns about valuation and competition. Recent ratings from firms like Rosenblatt, UBS, and Morgan Stanley have reaffirmed Buy or Overweight ratings, showing continued institutional support despite the stock's volatility.
Bulls vs Bears: CBRS Investment Factors
Cerebras presents a classic high-growth, high-risk investment. The bull case rests on explosive revenue growth, a massive backlog, and improving margins, while the bear case centers on extreme valuation, negative equity, and ongoing losses. Currently, the bear side has stronger evidence due to the unsustainable valuation and financial fragility, but the growth narrative is compelling. The key tension is whether Cerebras can grow into its valuation and achieve profitability before market sentiment turns, as any stumble could lead to severe de-rating.
Bullish
- Explosive Revenue Growth: Q1 2026 revenue surged 94.35% YoY to $193.4M, accelerating from prior quarters. This rapid growth, driven by AI infrastructure demand and partnerships with OpenAI and AWS, supports the company's high valuation.
- Massive Backlog and Strategic Partnerships: Cerebras has a $25 billion backlog, providing strong revenue visibility. Partnerships with OpenAI and AWS validate its technology and open large addressable markets, underpinning long-term growth potential.
- Improving Profitability Metrics: Gross margin improved to 44.56% in Q1 2026 from 41.81% a year ago, and net loss narrowed to $14.0M from $23.9M. This trend suggests operating leverage and a path toward profitability.
- Strong Analyst Conviction: With 11 analysts, consensus is Strong Buy (mean 1.45). Average target price of $290.73 implies 32.8% upside, and high target of $325 suggests even greater potential, reflecting institutional optimism.
Bearish
- Extreme Valuation Premium: Trailing PS ratio of 131.28x is over 13x the semiconductor industry average of ~10x. Even forward PS of 32.3x (based on $7.36B revenue) is expensive, leaving little room for error.
- Negative Equity and Debt Concerns: Debt-to-equity ratio is -0.45, indicating negative shareholder equity. This financial fragility, despite $2.75B cash, raises solvency questions and limits financial flexibility.
- Persistent Operating Losses: Operating margin is -7.77% in Q1 2026, and free cash flow was -$119.6M. Heavy R&D and sales spending (R&D alone $75.5M) may delay profitability and strain cash reserves.
- High Volatility and Downside Risk: Stock is down 12% from 52-week high and has already seen a max drawdown of -45.83%. With a short ratio of 2.26, sentiment is fragile, and any negative news could trigger sharp declines.
CBRS Technical Analysis
Cerebras has been in a pronounced downtrend since its IPO, with the stock currently trading at $218.98, down 12.03% from its 52-week high of $386.34. The stock is positioned at 28.4% of its 52-week range (calculated as (218.98-160.81)/(386.34-160.81)), indicating it is closer to the lows than the highs, reflecting a bearish sentiment. The 1-year price change is not available due to the recent listing, but the stock has already experienced a maximum drawdown of -45.83%, underscoring the high volatility and risk.
Beta
—
—
Max Drawdown
-45.8%
Largest decline past year
52-Week Range
$161-$386
Price range past year
Annual Return
—
Cumulative gain past year
| Period | CBRS Return | S&P 500 |
|---|---|---|
| 1m | +0.6% | +1.9% |
| 3m | -18.3% | +2.3% |
| 6m | — | +10.6% |
| 1y | — | +19.5% |
| ytd | — | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CBRS Fundamental Analysis
Cerebras reported Q1 2026 revenue of $193.4 million, a 94.35% YoY increase from $99.5 million in Q1 2025, demonstrating accelerating growth. However, the company remains unprofitable, with a net loss of $14.0 million in Q1 2026, though this loss narrowed significantly from the $23.9 million loss in Q1 2025. Gross margin improved to 44.56% in Q1 2026 from 41.81% in Q1 2025, but operating margin remains deeply negative at -7.77%, reflecting heavy R&D and sales investments. The company's balance sheet shows a current ratio of 2.15 and a negative debt-to-equity ratio of -0.45, indicating negative equity, which is a red flag. Free cash flow was negative at -$119.6 million in Q1 2026, but the company raised significant capital through its IPO, ending the quarter with $2.75 billion in cash.
Quarterly Revenue
$193406000.0B
2026-03
Revenue YoY Growth
+94.3%
YoY Comparison
Gross Margin
44.6%
Latest Quarter
Free Cash Flow
$145070500.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CBRS Overvalued?
Given the negative net income, we use the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 131.28x, while the forward PS ratio (based on estimated revenue of $7.36 billion) is approximately 32.3x, implying the market expects massive revenue growth. Compared to the semiconductor industry average PS ratio of around 10x, Cerebras trades at a significant premium, reflecting its high growth expectations. Historically, the PS ratio has ranged from 101x to 925x over the past year, and the current 131x is near the lower end, suggesting the stock may be relatively cheaper than its own history, but still extremely expensive on an absolute basis.
PE
758.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
848.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are substantial. The company has negative equity (debt-to-equity -0.45) and persistent operating losses (operating margin -7.77% in Q1 2026). Despite $2.75B cash from IPO, free cash flow was -$119.6M in Q1, indicating cash burn. Revenue concentration in AI infrastructure is high, with a few key customers like OpenAI and AWS, making it vulnerable to order cancellations or delays. The $25B backlog is promising but not guaranteed, and any contract renegotiation could impact revenue visibility.
FAQ
The key risks are: 1) Valuation risk - the stock could de-rate sharply if growth slows, given the extreme PS ratio. 2) Financial risk - negative equity and negative free cash flow could lead to dilution or liquidity issues. 3) Competitive risk - Nvidia and other players could erode market share. 4) Customer concentration - reliance on OpenAI and AWS for a large portion of revenue. The most severe risk is a combination of these, which could drive the stock down 30-40% from current levels.
Analysts have a Strong Buy rating with an average target of $290.73, implying 32.8% upside. Our 12-month outlook is balanced: a 25% chance of reaching $290-$325 (bull), a 50% chance of $220-$290 (base), and a 25% chance of $160-$220 (bear). The base case assumes continued strong growth but with valuation pressure. The most likely scenario is moderate upside, but the stock is highly volatile and could swing significantly in either direction.
CBRS is significantly overvalued on traditional metrics. The trailing PS ratio of 131.28x is over 13x the semiconductor industry average of ~10x. Even on a forward basis, the PS ratio of 32.3x is high, implying the market expects massive revenue growth. The stock is trading near the lower end of its historical PS range (101x-925x), suggesting it is relatively cheaper than its own past, but still expensive in absolute terms. The market is pricing in near-perfect execution and sustained triple-digit growth, leaving little room for disappointment.
CBRS is a high-risk, high-reward stock. With a Strong Buy consensus and 32.8% upside to the average target, it could be a good buy for aggressive growth investors who believe in the AI infrastructure story. However, the trailing PS ratio of 131x is extremely expensive, and the company has negative equity and operating losses. The stock is suitable only for those who can tolerate high volatility and have a long-term horizon. If you are risk-averse, it is better to wait for a more reasonable valuation or evidence of sustained profitability.
CBRS is more suitable for long-term investors with a high risk tolerance, given its extreme volatility and speculative nature. The stock has a beta that is likely high, and it has already experienced a -45.83% drawdown. Short-term trading is possible but extremely risky due to unpredictable swings. For long-term investors, a minimum holding period of 3-5 years is recommended to allow the company to grow into its valuation and potentially achieve profitability. However, position sizing should be small to manage risk.